Nkarta, Inc. (NASDAQ:NKTX) Shares Sold by New York Life Investment Management LLC

New York Life Investment Management LLC lessened its stake in Nkarta, Inc. (NASDAQ:NKTX) by 2.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 97,660 shares of the company’s stock after selling 2,634 shares during the period. New York Life Investment Management LLC’s holdings in Nkarta were worth $645,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NKTX. Innovis Asset Management LLC purchased a new position in shares of Nkarta in the 3rd quarter valued at approximately $193,000. Bleakley Financial Group LLC purchased a new position in Nkarta in the 4th quarter valued at $70,000. Bailard Inc. acquired a new position in Nkarta in the 4th quarter valued at $106,000. Acadian Asset Management LLC purchased a new position in Nkarta during the 3rd quarter worth $89,000. Finally, Simplicity Solutions LLC purchased a new position in Nkarta during the 4th quarter worth $70,000. 80.54% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Nkarta

In other Nkarta news, Director Simeon George bought 2,000,000 shares of the company’s stock in a transaction on Wednesday, March 27th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $20,000,000.00. Following the acquisition, the director now owns 1,548,341 shares of the company’s stock, valued at approximately $15,483,410. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Simeon George bought 2,000,000 shares of Nkarta stock in a transaction that occurred on Wednesday, March 27th. The shares were purchased at an average price of $10.00 per share, with a total value of $20,000,000.00. Following the purchase, the director now owns 1,548,341 shares in the company, valued at $15,483,410. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider James Trager sold 4,143 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $12.00, for a total value of $49,716.00. Following the transaction, the insider now directly owns 149,415 shares of the company’s stock, valued at approximately $1,792,980. The disclosure for this sale can be found here. Corporate insiders own 5.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on NKTX shares. Raymond James reiterated an “outperform” rating and set a $16.00 price target (up from $13.00) on shares of Nkarta in a research note on Friday, March 22nd. HC Wainwright cut their target price on Nkarta from $22.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, March 22nd. Needham & Company LLC restated a “buy” rating and issued a $15.00 price target on shares of Nkarta in a research note on Wednesday, April 10th. Canaccord Genuity Group increased their price objective on Nkarta from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, March 26th. Finally, Mizuho reduced their target price on Nkarta from $31.00 to $25.00 and set a “buy” rating for the company in a report on Friday, March 22nd. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $17.83.

Nkarta Price Performance

Shares of NASDAQ:NKTX opened at $6.40 on Thursday. The firm has a market capitalization of $316.29 million, a price-to-earnings ratio of -2.67 and a beta of 0.88. The business’s 50 day simple moving average is $9.99 and its 200-day simple moving average is $7.27. Nkarta, Inc. has a 12 month low of $1.28 and a 12 month high of $16.24.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.05. On average, equities analysts anticipate that Nkarta, Inc. will post -2.36 earnings per share for the current year.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.